Quince Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Quince Therapeutics, Inc. carries a market capitalization of 4.73M, placing it among publicly traded companies globally. Its enterprise value stands at -11.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.73M |
| Enterprise Value | -11.27M |
Share Statistics
Quince Therapeutics, Inc. currently has 689,539.00 shares outstanding.
| Shares Outstanding | 689,539.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | -0.17 |
| P/OCF Ratio | -0.16 |
Financial Position
Quince Therapeutics, Inc. maintains a current ratio of 2.92, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.92 |
| Quick Ratio | 2.82 |
| Debt / Equity | 2.59 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -49.42 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -2.17M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Quince Therapeutics, Inc.'s stock has declined approximately -94.79141% over the past 52 weeks. The 50-day moving average sits at 21.92, while the 200-day moving average is 247.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.79141% |
| 50-Day Moving Average | 21.92 |
| 200-Day Moving Average | 247.31 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -48.46M, while operating income came in at -48.61M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -48.61M |
| Pretax Income | -35.21M |
| Net Income | -33.04M |
| EBITDA | -48.46M |
| EBIT | -48.61M |
| Earnings Per Share (EPS) | -102.95 |
Balance Sheet
Quince Therapeutics, Inc. holds 18.16M in cash and equivalents against 406,000.00 in total debt, resulting in a net debt position of -18.16M. Total book value stands at -424.52M, with working capital of 16.81M providing operational flexibility.
| Cash & Cash Equivalents | 18.16M |
| Total Debt | 406,000.00 |
| Net Debt | -18.16M |
| Equity (Book Value) | -424.52M |
| Book Value Per Share | -1,322.91 |
| Working Capital | 16.81M |
Cash Flow
Quince Therapeutics, Inc. produced -39.45M in operating cash flow over the past twelve months. After subtracting -204,000.00 in capital expenditures, free cash flow totaled -39.65M - equivalent to -123.57 per share.
| Operating Cash Flow | -39.45M |
| Capital Expenditures | -204,000.00 |
| Free Cash Flow | -39.65M |
| FCF Per Share | -123.57 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -420.61 |
| FCF Yield | -605.46 |
Stock Splits
Quince Therapeutics, Inc.'s most recent stock split took place on June 30, 2026 with a 20:1 split ratio.
| Last Split Date | 6/30/2026 |
| Split Ratio | 20:1 |
Scores
Quince Therapeutics, Inc. posts an Altman Z-Score of -27.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -27.24 |